Compound ID | 1188
Class: DNA synthesis inhibitor
Spectrum of activity: | Gram-positive |
Details of activity: | Effective agfainst resistant Steptococci, Staphylococci and Enterococci. This novel class of antimicrobials works by binding the minor groove of bacterial DNA/ |
Description: | Ravic. M., Firmin. D., Suckling. C., Hunter. I., Lundberg. C., Jensen. K. "in vivo Antimicrobial Activity of MGB-BP-3, a New Class of Antibacterial Agent, in Murine Infection Models " Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2015. |
Institute where first reported: | MGB Biopharma |
Year first mentioned: | 2015 |
Highest developmental phase: | Phase 2 (NCT03824795) |
Development status: | Active (as of 2025) |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/23730143 |
Guide to Pharmacology: | MGB-BP-3 |
Citation: | http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3798&sKey=066fe91c-1dff-48d2-a97e-9d682ce3a71c&cKey=fdd5720d-09af-4149-b38d-31789e10af21&mKey=7a574a80-eab1-4b50-b343-4695df14907e |